{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:37:29Z","timestamp":1787027849460,"version":"build-2736575974"},"reference-count":24,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alveolus Biomedical BV"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background: Children with cystic fibrosis (CwCF) are at increased risk of fat-soluble vitamin (FSV) deficiency due to fat malabsorption. In France, children were usually supplemented with multiple individual vitamin preparations but have recently converted to DEKAs Plus Liquid (DPL), an absorption-enhanced, CF-specific, multivitamin formulation that includes vitamins D3, E, K1, A (beta-carotene and retinol), B, C, zinc, and selenium. We evaluated the impact of this change on FSV levels, treatment satisfaction, and compliance. Methods: Young CwCF (n = 39, mean age 2.3 \u00b1 1.1 years) were analyzed retrospectively. Serum FSV levels, prothrombin time, treatment satisfaction, and compliance were assessed at baseline (M0) and after 12 months (M12). Results: Paired data analysis was performed on the 34 who completed 12 months. After 3 months, the initial daily dose was adjusted in nine cases. Median (interquartile range) serum levels of vitamin E (19.3 (17\u201327) vs. 26.3 (20\u201331) \u00b5mol\/L, p = 0.0002) and 25-hydroxyvitamin D (80.2 (68\u201391) vs. 88.5 (79\u2013108) nmol\/L, p = 0.04) increased. Prothrombin time and vitamin A levels showed no significant change (p = 0.7, p = 0.4, respectively). The total number of FSV deficiencies decreased from 10 to 1, vitamin D deficiency was eliminated, and vitamin K1 supplementation increased from 76% to 100% (p = 0.008). The median treatment satisfaction score (VAS1\u201310) improved from 7 (5\u20139) to 9 (9\u201310) (p = 0.0006). Patient compliance remained high (9.5 (8.5\u201310) vs. 10 (9\u201310), p = 0.4). Conclusions: Switching from individual vitamins to DPL reduced vitamin deficiencies and improved FSV levels and patient satisfaction.<\/jats:p>","DOI":"10.3390\/children12091149","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:01:01Z","timestamp":1756454461000},"page":"1149","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of a Cystic Fibrosis Specific Multivitamin Formulation on Fat-Soluble Vitamin Status and Treatment Satisfaction in Young Children"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2331-278X","authenticated-orcid":false,"given":"Anne","family":"Munck","sequence":"first","affiliation":[{"name":"Hospital Necker Enfants Malades, CF Center, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Enaud","sequence":"additional","affiliation":[{"name":"Hospital Pellegrin-Enfants, CF Center, CIC, 33000 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4646-018X","authenticated-orcid":false,"given":"Jeanne","family":"Languepin","sequence":"additional","affiliation":[{"name":"CHU Dupuytren, CF Center, 87000 Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4849-9034","authenticated-orcid":false,"given":"Natascha","family":"Remus","sequence":"additional","affiliation":[{"name":"Intercommunal Hospital, Center on Rare Respiratory Diseases, 94000 Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Wizla","sequence":"additional","affiliation":[{"name":"University Hospital Lille, Paediatric CF Center, 59037 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Chedevergne","sequence":"additional","affiliation":[{"name":"Hopital Necker-Enfants Malades, CF Center, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3576-2518","authenticated-orcid":false,"given":"Stephanie","family":"Bui","sequence":"additional","affiliation":[{"name":"Hopital Pellegrin, Paediatric CF Center, 33000 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Arrouy","sequence":"additional","affiliation":[{"name":"University Hopital des Enfants, CIC, 31300 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Mittaine","sequence":"additional","affiliation":[{"name":"University Hopital des Enfants, Paediatric CF Center, 31300 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, College of Public Health, East Tennessee State University, Johnson City, TN 37614, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wahlquist","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, College of Public Health, Center for Rural Health and Research, East Tennessee State University, Johnson City, TN 37614, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[{"name":"Hopital Necker-Enfants Malades, CF Center, Inserm U1151, Universite Paris Cite, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jcf.2007.07.002","article-title":"Vitamin A intake and elevated serum retinol levels in children and young adults with cystic fibrosis","volume":"7","author":"Maqbool","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40348-024-00178-6","article-title":"Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis\u2014A real-life insight","volume":"11","author":"Fabricius","year":"2024","journal-title":"Mol. Cell. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/0884533614530170","article-title":"Relationship between fat-soluble vitamin supplementation and blood concentrations in adolescent and adult patients with cystic fibrosis","volume":"29","author":"Siwamogsatham","year":"2014","journal-title":"Nutr. Clin. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jcf.2023.04.019","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis","volume":"22","author":"Schembri","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Francalanci, M., and Terlizzi, V. (2023). Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators. Children, 10.","DOI":"10.3390\/children10020252"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jcf.2023.08.002","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis","volume":"22","author":"Hergenroeder","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10620-006-9489-2","article-title":"Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients","volume":"52","author":"Papas","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jcf.2007.05.001","article-title":"A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis","volume":"7","author":"Papas","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jcf.2010.09.005","article-title":"Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis","volume":"10","author":"Sagel","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.anpedi.2015.04.016","article-title":"Evaluation of the usefulness of a standard multivitamin supplement designed for patients with cystic fibrosis","volume":"83","author":"Garriga","year":"2015","journal-title":"An. Pediatr. (Barc.)"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.201801-0105OC","article-title":"Effects of an antioxidant-enriched multivitamin in Cystic Fibrosis: A randomized, controlled, multicenter clinical trial","volume":"198","author":"Sagel","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejps.2013.02.006","article-title":"The applications of Vitamin E TPGS in drug delivery","volume":"49","author":"Guo","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2015). Scientific opinion on Dietary Reference Values for vitamin A. EFSA J., 13, 4028.","DOI":"10.2903\/j.efsa.2015.4028"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2014). Scientific opinion on the essential composition of infant and follow-on formulae. EFSA J., 12, 3760.","DOI":"10.2903\/j.efsa.2014.3760"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/ppul.25825","article-title":"Vitamins A, D, E status as related to supplementation and lung disease markers in young children with Cystic Fibrosis","volume":"57","author":"Lai","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/0016-5085(93)90652-S","article-title":"Multicenter trial of d-\u03b1-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis","volume":"104","author":"Sokol","year":"1993","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Suchy, F., and Sokol, R. (2014). Medical and nutritional management of cholestasis in infants and children. Liver Disease in Children, Cambridge University Press.","DOI":"10.1017\/CBO9781139012102"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1203\/00006450-199202000-00011","article-title":"D-Alpha-tocopheryl polyethylene glycol-1000 succinate enhances the absorption of vitamin D in chronic cholestatic liver disease of infancy and childhood","volume":"31","author":"Argao","year":"1992","journal-title":"Pediatr. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/hep.20864","article-title":"Comparison of indices of vitamin A status in children with chronic liver disease","volume":"42","author":"Feranchak","year":"2005","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1210\/jc.2004-0360","article-title":"Vitamin D2 is much less effective than vitamin D3 in humans","volume":"89","author":"Armas","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/thorax.56.1.48","article-title":"Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis","volume":"56","author":"Renner","year":"2001","journal-title":"Thorax"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MCP.0b013e3283136787","article-title":"Update on fat-soluble vitamins in cystic fibrosis","volume":"14","author":"Maqbool","year":"2008","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ppul.25781","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on vitamin D absorption in cystic fibrosis patients","volume":"57","author":"Wright","year":"2022","journal-title":"Pediatr. Pulmonol."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/9\/1149\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:35:00Z","timestamp":1760034900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/9\/1149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["children12091149"],"URL":"https:\/\/doi.org\/10.3390\/children12091149","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}